A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

ABT-126

ABT-126 Low Dose

DRUG

ABT-126

ABT-126 High Dose

DRUG

Placebo

Placebo

Trial Locations (20)

10065

Site Reference ID/Investigator# 73982, New York

11516

Site Reference ID/Investigator# 72700, Cedarhurst

30308

Site Reference ID/Investigator# 75654, Atlanta

32751

Site Reference ID/Investigator# 75146, Maitland

34201

Site Reference ID/Investigator# 75314, Bradenton

60169

Site Reference ID/Investigator# 76534, Hoffman Estates

60640

Site Reference ID/Investigator# 72703, Chicago

63109

Site Reference ID/Investigator# 73981, St Louis

70629

Site Reference ID/Investigator# 73984, Lake Charles

73116

Site Reference ID/Investigator# 113035, Oklahoma City

75115

Site Reference ID/Investigator# 72702, DeSoto

77008

Site Reference ID/Investigator# 75147, Houston

90502

Site Reference ID/Investigator# 72701, Torrance

91710

Site Reference ID/Investigator# 74436, Chino

91950

Site Reference ID/Investigator# 72699, National City

92056

Site Reference ID/Investigator# 73983, Oceanside

92102

Site Reference ID/Investigator# 86974, San Diego

92845

Site Reference ID/Investigator# 72704, Garden Grove

92868

Site Reference ID/Investigator# 73236, Orange

08053

Site Reference ID/Investigator# 89553, Marlton

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01678755 - A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia | Biotech Hunter | Biotech Hunter